Renalytix to Present at H.C. Wainwright 24th Annual Global Investment Conference
Renalytix plc (NASDAQ: RNLX) announced its participation in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Renalytix plc (NASDAQ: RNLX) announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference, scheduled for September 12-14, 2022. The company will hold a fireside chat, available for live and archived viewing starting at 7:00 a.m. Eastern Time on September 12, 2022, via the Company's website.
Renalytix, a leader in bioprognosis for kidney health, has developed the KidneyIntelX test to assess the risk of rapid kidney function decline in adults with Type 2 diabetes and early stages of chronic kidney disease.
Details
News Market Reaction – RNLX
The recorded move for RNLX in the trading session of this news was -0.59%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK and SALT LAKE CITY, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the company will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference to be held September 12-14, 2022. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the Company’s website at https://investors.renalytix.com beginning at 7:00 a.m. Eastern Time on September 12, 2022.
About Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory-developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D with early CKD stages 1-3. We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.
For further information, please contact:
| Renalytix plc | www.renalytix.com |
| James McCullough, CEO | Via Walbrook PR |
| Stifel (Nominated Adviser, Joint Broker) | Tel: 020 7710 7600 |
| Alex Price / Nicholas Moore | |
| Investec Bank plc (Joint Broker) | Tel: 020 7597 4000 |
| Gary Clarence / Daniel Adams | |
| Walbrook PR Limited | Tel: 020 7933 8780 or renalytix@walbrookpr.com |
| Paul McManus / Lianne Applegarth / Alice Woodings | Mob: 07980 541 893 / 07584 391 303 / 07407 804 654 |
| CapComm Partners | Tel: 415-389-6400 or investors@renalytix.com |
| Peter DeNardo |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.